168 related articles for article (PubMed ID: 27398862)
1. CROI 2016: Viral Hepatitis and Liver Fibrosis.
Luetkemeyer AF; Wyles DL
Top Antivir Med; 2016; 24(1):47-58. PubMed ID: 27398862
[TBL] [Abstract][Full Text] [Related]
2. CROI 2014: Viral hepatitis and complications of HIV disease and antiretroviral therapy.
Luetkemeyer AF; Havlir DV; Currier JS
Top Antivir Med; 2014 May; 22(2):602-15. PubMed ID: 24901886
[TBL] [Abstract][Full Text] [Related]
3. CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
Luetkemeyer AF; Havlir DV; Currier JS
Top Antivir Med; 2013; 21(2):62-74. PubMed ID: 23681961
[TBL] [Abstract][Full Text] [Related]
4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
5. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
6. HIV/HCV coinfection: a new era of treatment.
Highleyman L
BETA; 2011; 23(4):30-47. PubMed ID: 22567825
[TBL] [Abstract][Full Text] [Related]
7. New hepatitis C therapies for special patient populations.
Soriano V; Labarga P; de Mendoza C; Fernández-Montero JV; Esposito I; Benítez-Gutiérrez L; Peña JM; Barreiro P
Expert Opin Pharmacother; 2016; 17(2):217-29. PubMed ID: 26595348
[TBL] [Abstract][Full Text] [Related]
8. CROI 2017: Highlights of Advances in Viral Hepatitis and Liver Fibrosis.
Luetkemeyer AF; Wyles DL
Top Antivir Med; 2017; 25(2):84-92. PubMed ID: 28598793
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Treatment Outcomes in Persons With HIV and Decompensated Cirrhosis Using a Collaborative Multidisciplinary HIV-Centered Approach.
Cachay ER; Mena A; Morano L; Benitez L; Maida I; Mendoza C; Hill L; Torriani F; Soriano V; Mathews WC;
J Int Assoc Provid AIDS Care; 2021; 20():23259582211024771. PubMed ID: 34132142
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus and coinfection with hepatitis B and C.
Petty LA; Steinbeck JL; Pursell K; Jensen DM
Infect Dis Clin North Am; 2014 Sep; 28(3):477-99. PubMed ID: 25151567
[TBL] [Abstract][Full Text] [Related]
11. Benefit of direct-acting antiviral therapy for hepatitis C virus (HCV) in monoinfected and HIV-HCV-coinfected patients with mixed cryoglobulinaemia.
Miailhes P; Hartig-Lavie K; Virlogeux V; Pradat P; Diakite M; Uhres AC; Zoulim F; Sarda MN
Clin Microbiol Infect; 2018 Nov; 24(11):1215.e1-1215.e4. PubMed ID: 29870852
[TBL] [Abstract][Full Text] [Related]
12. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
13. Advances in the treatment of HIV/HCV coinfection in adults.
Schlabe S; Rockstroh JK
Expert Opin Pharmacother; 2018 Jan; 19(1):49-64. PubMed ID: 29252031
[TBL] [Abstract][Full Text] [Related]
14. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Moll A; Jäger H; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Med; 2018 Apr; 19(4):299-307. PubMed ID: 29368456
[TBL] [Abstract][Full Text] [Related]
15. Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.
Meissner EG
Curr Opin Gastroenterol; 2017 May; 33(3):120-127. PubMed ID: 28234770
[TBL] [Abstract][Full Text] [Related]
16. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
17. HIV-coinfected patients respond worse to direct-acting antiviral-based therapy against chronic hepatitis C in real life than HCV-monoinfected individuals: a prospective cohort study.
Neukam K; Morano-Amado LE; Rivero-Juárez A; Mancebo M; Granados R; Téllez F; Collado A; Ríos MJ; de Los Santos-Gil I; Reus-Bañuls S; Vera-Méndez F; Geijo-Martínez P; Montero-Alonso M; Suárez-Santamaría M; Pineda JA
HIV Clin Trials; 2017 May; 18(3):126-134. PubMed ID: 28599618
[TBL] [Abstract][Full Text] [Related]
18. Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Cheng EY; Saab S; Holt CD; Busuttil RW
Expert Opin Pharmacother; 2015; 16(18):2835-48. PubMed ID: 26646975
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
20. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
